Download PDF
Nuklearmedizin 2008; 47(03): 132-138
DOI: 10.3413/nukmed-0311
Originalarbeiten - Original Articles
Schattauer GmbH

Procedure guidelines for MIBG-scintigraphy in children

Leitlinie zur MIBG-Szintigraphie bei Kindern
C. Franzius
1   Universitätsklinika Münster
2   Universitätsklinika MR- und PET/CT-Zentrum Bremen-Mitte
6   Deutsche Gesellschaft für Nuklearmedizin (DGN)
,
M. Schmidt
3   Universitätsklinika Köln
6   Deutsche Gesellschaft für Nuklearmedizin (DGN)
,
B. Hero
4   Universitätsklinika Klinik u. Poliklinik für Kinderheilkunde, Kinderonkologie u. -hämatologie, Universitätsklinikum Köln
7   Neuroblastom-Studiengruppe der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) Kliniken und Polikliniken für Nuklearmedizin
,
T. Pfluger
5   Universitätsklinika Ludwig-Maximilians-Unversität München
6   Deutsche Gesellschaft für Nuklearmedizin (DGN)
,
K. Hahn
5   Universitätsklinika Ludwig-Maximilians-Unversität München
6   Deutsche Gesellschaft für Nuklearmedizin (DGN)
› Author Affiliations
Further Information

Publication History

Eingegangen: 14 March 2008

Publication Date:
04 January 2018 (online)

Also available at
    Permissions and Reprints

Summary

The German translation of the EANM guideline for MIBG scintigraphy in children (Olivier P et al. EJNM MI 2003; 30: B45–B50; Hahn K. Der Nuklearmediziner 2002; 25: 101–105) was reviewed and actualized according to current publications, legal requirements and conditions in Germany. For the first time this guideline was generated in consensus with the neuroblastoma study group of the Association of Paediatric Haematologie and Oncology (GPOH) with the result of an interdisciplinary recommendation. Further main alterations are related to the recommended 123I activities with respect to the new EANM Paediatric Dosage Card and the explicit recommendation of SPECT.

Zusammenfassung

Die Leitlinie der EANM zur MIBG-Szintigraphie bei Kindern (Olivier P et al. EJNM MI 2003; 30: B45–B50) in ihrer deutschen übersetzung durch K. Hahn (Der Nuklearmediziner 2002; 25: 101–105) wurde anhand der aktuellen Datenlage sowie der gesetzlichen Rahmenbedingungen und Gegebenheiten in Deutschland überarbeitet und aktualisiert. Erstmals wurde in Deutschland die Empfehlung im Konsens mit der Neuroblastomstudiengruppe der Gesellschaft für Pädiatrische Hämatologie und Onkologie (GPOH) formuliert und damit auf eine interdisziplinäre Ebene gehoben. Weitere wesentliche Neuerungen betreffen die empfohlenen 123I-Aktivitäten unter Berücksichtigung der aktuellen Paediatric Dosage Card der EANM und die ausdrückliche Empfehlung der SPECT.

Keywords

MIBG scintigraphy - neuroblastoma - childhood - guideline

Schlüsselwörter

MIBG-Szintigraphie - Neuroblastom - Kindesalter - Verfahrensanweisung
 

  • Literatur

  • 1 Diagnostische Referenzwerte in der Nuklearmedizin. Empfehlungen der Strahlenschutzkommission-Verabschiedet in der 167. Sitzung der Strahlenschutzkommission am 6./7. Juli 2000 2000
    PubMedSearch in Google Scholar
  • 2 Bonnin F, Lumbroso J, Tenenbaum F. et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994; 35: 803-810.
    PubMedSearch in Google Scholar
  • 3 Franzius C, Hermann K, Weckesser M. et al. Whole-body PET/CT with C-11-meta-hydroxyephe- drine in tumors of the sympathetic nervous system: feasibility study and comparison with I-123-mIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642.
    PubMedSearch in Google Scholar
  • 4 Franzius C, Juergens K, Schober O. Is PET/CT necessary in paediatric oncology? For. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
    CrossrefPubMedSearch in Google Scholar
  • 5 Franzius C, Lang K, Wormanns D. et al. PET/CT and PET - application in pediatric oncology. Der Nuklearmediziner 2004; 27: 315-323.
    Thieme ConnectSearch in Google Scholar
  • 6 Franzius C, Riemann B, Vormoor J. et al. Metasta- tic neuroblastoma demostrated by whole-body PET-CT using C-11-HED. Nuklearmedizin 2005; 44: N4-N5.
    PubMedSearch in Google Scholar
  • 7 Gelfand M. I-123-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 2004; 34: 577-579.
    CrossrefPubMedSearch in Google Scholar
  • 8 Gelfand M. Meta-iodobenzylguanidine in children. Semin Nucle Med 1993; 23: 231-242.
    Search in Google Scholar
  • 9 Gelfand M, Elgazzar A, Kriss V. et al. Iodine- 123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753-1757.
    PubMedSearch in Google Scholar
  • 10 Geoerger B, Hero B, Harms D. et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001; 91: 1905-1913.
    CrossrefPubMedSearch in Google Scholar
  • 11 Giammarile F, Boneu A, Edeline V. et al. Guide de realisation de la scintigraphie a la meta-iodoben- zylguanidine (mIBG) en oncologie pediatrique. Med Nucl 2000; 24: 35-41.
    Search in Google Scholar
  • 12 Giammarile F, Lumbroso J, Ricard M. et al. Radio- iodinated metaiodobenzylguanidine in neuroblastoma: influence of high-dose on tumour site detection. Eur J Nucl Med 1995; 22: 1180-1183.
    CrossrefPubMedSearch in Google Scholar
  • 13 Gordon I, Peters A, Gutman A. et al. Skeletal assessment in neuroblastoma-the pitfalls of iodi-ne-123-MIBG scans. J Nucl Med 1990; 31: 129-134.
    PubMedSearch in Google Scholar
  • 14 Hahn K, Pfluger T. Is PET/CT necassary in pae- diatric oncology? Against. Eur J Nucl Med Mol Imaging 2006; 33: 966-968.
    CrossrefPubMedSearch in Google Scholar
  • 15 Hero B, Berthold F, Engert H. et al. Neuroblastom. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Gesellschaft für Pädiatrische Onkologie und Hämatologie. 2005
    PubMedSearch in Google Scholar
  • 16 Hickeson M, Charron M, Maris J. et al. Biodistribution of post-therapeutic versus diagnostic I-131-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004; 42: 268-274.
    CrossrefPubMedSearch in Google Scholar
  • 17 Hoefnagel C, De Kraker J, Valdes Olmos R. et al. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39 (Suppl 1) 61-64.
    PubMedSearch in Google Scholar
  • 18 Hoegerle S, Nitzsche E, Altehoefer C. et al. Pheo- chromocytomas: detection with 18F-DOPA whole-body PET - initial results. Radiology 2002; 222: 507-512.
    CrossrefPubMedSearch in Google Scholar
  • 19 Jacobs A, Delree M, Desprechins B. et al. Consolidating the role of I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol 1990; 20: 157-159.
    CrossrefPubMedSearch in Google Scholar
  • 20 Kaarsch P, Spix C. Deutsches Kinderkrebsregister, Jahresbericht 2005. Berlin: Buchdruckerei Johannes Krüger OHG; 2006
    Search in Google Scholar
  • 21 Khafagi F, Shapiro B, Fischer M. et al. Phaeochromo- cytoma and functioning paraganglioma in childhood and adolescence: role ofiodine 131 metaiodobenzylguanidine. Eur J Nucl Med 1991; 18: 191-198.
    CrossrefPubMedSearch in Google Scholar
  • 22 Khafagi F, Shapiro B, Gross M. The adrenal gland. In: Maisey M, Britton K, Gilday D. (eds) Clinical Nuclear Medicine. London: Chapman & Hall; 1989: 271-291.
    Search in Google Scholar
  • 23 Kinnier-Wilson L, Draper G. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J 1974; 3: 301-307.
    CrossrefPubMedSearch in Google Scholar
  • 24 Knickmeier M, Schäfers M, Schober O. Two years' experience using no-carrier-added meta- [I-123]iodobenzylguanidine in clincal studies. Eur J Nucl Med 2001; 28: 941.
    CrossrefPubMedSearch in Google Scholar
  • 25 Kushner B, Cheung N. Exploiting the MIBG-avi- dity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 2006; 47: 863-864.
    CrossrefPubMedSearch in Google Scholar
  • 26 Kushner B, Yeh S, Kramer K. et al. Impact of me- taiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086.
    CrossrefPubMedSearch in Google Scholar
  • 27 Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004; 45: 1172-1188.
    PubMedSearch in Google Scholar
  • 28 Kushner BH, Yeung HW, Larson SM. et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18-fluoro- deoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405.
    CrossrefPubMedSearch in Google Scholar
  • 29 Lassmann M, Biassoni L, Monieurs M. et al. The New EANM Dosage Card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798.
    CrossrefPubMedSearch in Google Scholar
  • 30 Leung A, Shapiro B, Hattner R. et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38: 1352-1357.
    PubMedSearch in Google Scholar
  • 31 Lumbroso J, Giammarile F, Hartmann O. et al. Upper clavicular and cardiac meta-[123I]iodobenzyl- guanidine uptake in children. Q J Nucl Med 1995; 39: 17-20.
    PubMedSearch in Google Scholar
  • 32 Lumbroso J, Guermazi F, Hartmann O. et al. Metaiodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988; 271: 689-705.
    PubMedSearch in Google Scholar
  • 33 Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]-metaiodo-benzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991; 35: 220-223.
    PubMedSearch in Google Scholar
  • 34 Mairs R. Neuroblastoma therapy using radiolabeled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents. Eur J Cancer 1999; 35: 1171-1173.
    CrossrefPubMedSearch in Google Scholar
  • 35 Mairs RJ, Cunningham SH, Russell J. et al. No- carrier-added Iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095.
    PubMedSearch in Google Scholar
  • 36 Moyes J, McCready V, Fullbrook A. Neuroblastoma MIBG in its diagnosis and management. Berlin: Springer; 1989
    Search in Google Scholar
  • 37 Nakajo M, Shapiro B, Copp J. et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682.
    PubMedSearch in Google Scholar
  • 38 Okuyama C, Ushijima Y, Kubota T. et al. I-123-Metaiodobenzylguanidine uptake in the nape of the neck of children: likly visualization of brown adipose tissue. J Nucl Med 2003; 44: 1421-1425.
    PubMedSearch in Google Scholar
  • 39 Owens J, Bolster AA, Prosser JE. et al. No-carrier- added I-123-MIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 2000; 21: 437-440.
    CrossrefPubMedSearch in Google Scholar
  • 40 Parisi M, Greene M, Dykes T. et al. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992; 27: 768-773.
    CrossrefPubMedSearch in Google Scholar
  • 41 Perel Y, Conway J, Kletzel M. et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18.
    CrossrefPubMedSearch in Google Scholar
  • 42 Pfluger T, Schmied C, Porn U. et al. Integrated imaging using MRI and I-123-metaiodobenzyl- guanidine scintigraphy to improve sensitivity and specificity in the diagnodid of pediatric neuroblastoma. Am J Roentgenol 2003; 181: 1115-1124.
    CrossrefPubMedSearch in Google Scholar
  • 43 Piepsz A, Hahn K, Roca I. et al. A radiopharma- ceutical schedule for image in pediatric. Recommendations of the pediatric task group of the European Association of Nuclear Medicine. Eur J Nucl Med 1990; 17: 127-129.
    CrossrefPubMedSearch in Google Scholar
  • 44 Pintelon H, Jonckheer M, Piepsz A. Paediatric nuclear medicine procedures: routine sedation or management of anxiety. Nucl Med Commun 1994; 15: 664-666.
    CrossrefPubMedSearch in Google Scholar
  • 45 Rufini V, Fisher G, Shulkin B. et al. Iodine- 123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996; 37: 1464-1468.
    PubMedSearch in Google Scholar
  • 46 Rufini V, Giordano A, Di Giuda D. et al. [123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 4: 25-28.
    Search in Google Scholar
  • 47 Schmidt M, Eschner W, Dietlein M. et al. Konventionelle nuklearmedizinische Tumordiagnostik (Tumor-SPECT): Was ist angesichts von F-18-FDG-PET noch aktuell?. Nuklearmedizin 2005; 44: 37-48.
    PubMedSearch in Google Scholar
  • 48 Schmidt M, Simon T, Hero B. et al. Is there a benefit of I-131-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-151.
    Thieme ConnectPubMedSearch in Google Scholar
  • 49 Shapiro B, Copp J, Sisson J. et al. Iodine-131 meta- iodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-585.
    PubMedSearch in Google Scholar
  • 50 Shulkin B, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39: 679-688.
    PubMedSearch in Google Scholar
  • 51 Shulkin BL, Hutchinson RJ, Castle VP. et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750.
    CrossrefPubMedSearch in Google Scholar
  • 52 Shulkin BL, Koeppe RA, Francis IR. et al. Pheo- chromocytomas that do not accumulate metai- odobenzylguanidine: Localization with PET and administration of FDG. Radiology 1993; 186: 711-715.
    CrossrefPubMedSearch in Google Scholar
  • 53 Shulkin BL, Wieland DM, Baro ME. et al. PET Hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996; 37: 16-21.
    PubMedSearch in Google Scholar
  • 54 Shulkin BL, Wieland DM, Schwaiger M. et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 1992; 33: 1125-1131.
    PubMedSearch in Google Scholar
  • 55 Sisson J, Shulkin B. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43: 217-223.
    PubMedSearch in Google Scholar
  • 56 Solanki K, Bomanji J, Moyes J. et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodo- benzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.
    CrossrefPubMedSearch in Google Scholar
  • 57 Stabin M, Gelfand M. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42: 93-112.
    PubMedSearch in Google Scholar
  • 58 Trampal C, Engler H, Juhlin C. et al. Pheochromo- cytomas: Detection with C-11 hydroxyephedrine PET. Radiology 2004; 230: 423-428.
    CrossrefPubMedSearch in Google Scholar
  • 59 Wieland D, Wu J, Brown L. et al. Radiolabeled adrenergi neuron-blocking agents: adrenomedul- lary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
    PubMedSearch in Google Scholar
  • 60 Young JJ, Ries L, Silverberg E. et al. Cancer incidence, survival, and mortality for children younger than age 15years. Cancer 1986; 58 (Suppl 2) 598-602.
    CrossrefPubMedSearch in Google Scholar